- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01504542
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
November 20, 2013 updated by: Heat Biologics
A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)
This study will enroll patients with locally advanced or metastatic non-EGFR mutated Non-Small Cell Lung Cancer (NSCLC) lung cancer after failure of at least one but no more than two prior approved treatment regimens.
Patients will be randomized to receive one of two doses of vaccine or placebo to be dosed twice weekly for 18 weeks (36 doses total) and patients will also receive erlotinib 150mg taken orally once daily for the duration of the trial.
The study will examine the immune effects, safety and efficacy of two different doses of HS110 vaccine in combination with erlotinib versus erlotinib alone.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This multicenter, randomized, double-blind, placebo-controlled study will enroll patients with advanced NSCLC (squamous cell or non-squamous cell) without EGFR mutations (either L858R or 746-750 deletions) who have had progression or recurrence of their disease following at least one but no more than two prior regimens (adjuvant therapy excluded) of approved therapy that did not include immunomodulating or anti-EGFR targeted therapy for their disease.
EFGR status must be known at the time of enrollment either via prior determination or testing performed from archival tissue during the screening process.
Patients with resectable disease will eligible if resection can be deferred for the first six weeks of vaccine.
Patients will receive twice weekly dosing of vaccine (spatially divided as 5 intradermal injections) for 18 weeks (36 total doses).
Patients will be randomized in a 2:1 fashion; with 30 patients in each of the HS110 treatments groups (high and low dose) and 15 patients will receive placebo injections.
Patients will also receive erlotinib 150mg once daily for the duration of the trial.
A total of 75 patients will be enrolled in the trial.
The study includes a lead-in phase of 9 patients (3 from each dosing group) who will be observed weekly for 4 weeks to assess the safety of combining HS110 with erlotinib.
Treatment of the first 4 patients will be staggered by 2 week intervals to allow for safety evaluation before treating additional patients.
If the combination of proves to be safe and well-tolerated in the first 9 patients, enrollment will be opened up to the predetermined sample size for each arm.
A Data Monitoring Committee (DMC) will be used in this study to independently monitor adverse events and progression/survival data.
The DMC will meet at the completion of the run-in period and after half the patients have been dosed through week 6 and week 12.
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75201
- Mary Crowley Cancer Research Centers
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to comply with the protocol and sign informed consent.
- Histologically or cytologically confirmed locally advanced or metastatic squamous cell or non-squamous cell NSCLC after at least one but no more than two prior regimens of approved therapy for their disease (not including adjuvant treatment).
- Confirmation that their disease has no known EGFR mutations based on documented prior analysis or study-specific analysis of archival tumor tissue.
- At least one site of bi-dimensionally measurable NSCLC disease.
- Patients with recurrent, resectable disease able to undergo six weeks of vaccine therapy prior to resection.
- Brain metastasis if present and treated must be stable by CT scn or MRI for at least 8 weeks.
- Age ≥ 18 years.
- EGOG performance status of 0-1.
- Lab parameters
- Albumin ≥ 3.5mg/dL
- Total Bilirubin < 1.5mg/dL
- Alanine transaminase (ALT), and aspartate transaminase(AST)≤ 2.5 x upper limits of normal or ≤ x ULN in case of liver metastases.
- Serum creatinine < 1.5mg/dL or calculated creatinine clearance >50 mL/minute per the Cockcroft-Gault formula.
White blood cell (WBC) count ≥ 4,000/mm3 with an absolute neutrophil count
- 1,500mm3.
- Hemoglobin ≥ 9g/dL
- Platelet count ≥ 100,000/mm3
- Women of childbearing potential or men of fathering potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide or surgical sterilization) during the study and for 6 months after receiving the last administration of study medication. Female patients of childbearing potential must test negative for pregnancy prior to enrolling in the trial. Post-menopausal (cessation of menses for more than 6 months) women are eligible for this study.
Exclusion Criteria:
- No prior therapy with EGFR-targeted drugs, including approved and investigational therapies, or prior immunologic or biologic response modifier therapy for treatment of their disease.
- Uncontrolled or untreated brain or spinal cord metastases or meningeal carcinomatosis.
- Known human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy.
- Autoimmunity syndromes (primary or acquired) including, but not limited to, the following: rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, or glomerulonephritis requiring active steroid or other immunosuppressive therapy.
- Known immunodeficiency disorders, either primary or acquired.
- Other malignancies present within the past 3 years, except for cutaneous basal and/or squamous cell carcinoma(s) or in situ cervical cancer.
- History of clinically significant cardiac impairment, congestive heart failure > New York Heart Association (NYHA) cardiac disease classification Class II, unstable angina, or myocardial infarction during the previous 6 months, or serious cardiac arrhythmia.
- Known alcohol or chemical abuse, or mental or psychiatric condition precluding compliance with the protocol.
- Chemotherapy, radiation, or other antitumor therapy during the last 4 weeks.
- Pregnant, nursing, or planning a pregnancy (both men and women) within 12 months of enrollment.
- Known allergy to soy or egg products.
- Patient is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose HS-110
2,000,000 cells/0.5mls
+ erlotinib 150mg orally once daily
|
0.5ml to be administered twice weekly for 18 weeks (36 doses)
0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
|
Experimental: High dose HS110
10,000,000 HS110 cells/0.5ml
+ erlotinib 150mg orally once daily.
|
0.5ml to be administered twice weekly for 18 weeks (36 doses)
0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
|
Placebo Comparator: Placebo vaccine + erlotinib 150mg orally once daily
Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
|
0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunologic Response (defined as production of IFNƴ from CD8+ T cells as evaluated by ELISPOT assay)
Time Frame: Week 18
|
Immune response will be evalulated by ELISPOT assays and change will be assessed from baseline.
|
Week 18
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the combination of HS110 vaccine and erlotinib
Time Frame: Up to 1 year
|
Incidence and severity of adverse events, changes in laboratory measures, physical exams and evaluation of autoimmune phenomena.
|
Up to 1 year
|
Tumor assessment by immunologic response criteria (irRC)
Time Frame: Baseline, Week 12 and Week 22
|
Patients will have a CT scan performed at baseline, Week 12 and Week 22 or at the end of study visit in the case of early termination from study.
Investigators will assess the disease response using irRC for overall response, CR, PR, SD or PD.
|
Baseline, Week 12 and Week 22
|
Exploratory Immunologic endpoint - evaluation of circulating tumor cells
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Analysis via a semiautomated, epithelial cell adhesion molecule-based immunomagnetic technique.
|
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Exploratory immunologic endpoint - immune function
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Analysis of cell surfance molecules by flow cytometry
|
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Exploratory immunologic endpoint - proteomic profile
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Examination of protein expression utilizing western blot, immunohistochemical staining, enzyme linked immunosorbent assay (ELISA) or mass spectrometry
|
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Nemunaitis, MD, Mary Crowley Cancer Research Centers
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
December 20, 2011
First Submitted That Met QC Criteria
January 4, 2012
First Posted (Estimate)
January 5, 2012
Study Record Updates
Last Update Posted (Estimate)
November 21, 2013
Last Update Submitted That Met QC Criteria
November 20, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS110-10-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
Clinical Trials on HS110 vaccine
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
Sinovac Biotech Co., LtdCompleted
-
GlaxoSmithKlineCompletedMalaria | Malaria VaccinesGhana, Burkina Faso
-
University of OxfordMalaria Research and Training Center, Bamako, MaliRecruiting
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico
-
Sun XinActive, not recruitingVaccine Adverse ReactionChina
-
GlaxoSmithKlineCompletedInfections, PapillomavirusFinland
-
University of California, San FranciscoCompletedHematopoietic Stem Cell TransplantUnited States
-
University of PretoriaUniversity of StellenboschActive, not recruiting
-
China National Biotec Group Company LimitedPeking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaboratorsCompletedEnterovirus Infections | InfluenzaChina